Key Takeaways
- • CORE Biomedicine closed a $21 million Series A financing round co-led by UTokyo Innovation Platform Co., Ltd. and Elikon Venture, with participation from eight additional institutional investors including Mitsubishi UFJ Capital and CD Capital.
- • The company received a competitive grant award from Japan's Agency for Medical Research and Development (AMED) under the Strengthening Program for Pharmaceutical Startup Ecosystem, providing non-dilutive funding to support R&D and university/hospital partnerships.
- • CORE's lineage-based precision oncology approach targets core cancer drivers with potential to expand patient populations eligible for treatment, positioning the company to advance lead programs through discovery and early clinical development.
- • The dual funding sources—venture capital and government grant support—strengthen CORE's development runway while capitalizing on Japan's biotech ecosystem support and global investor confidence in precision medicine platforms.
Summary
CORE Biomedicine, a Boston-based biotechnology company focused on precision oncology, announced the completion of a $21 million Series A financing round on July 28, 2026. The round was co-led by UTokyo Innovation Platform Co., Ltd. and Elikon Venture Capital, with additional support from InnoPinnacle Fund, Mitsubishi UFJ Capital Co., Ltd., Suzhou Capital Group Co., Ltd., CD Capital, YuanBio Venture Capital, Vision Incubate Co., Ltd., and Root Venture Partners. The diverse investor syndicate reflects geographic and institutional backing spanning Japan, China, and global venture platforms.
Complementing the venture round, CORE Biomedicine Japan—a wholly owned subsidiary—secured a grant award under Japan's Strengthening Program for Pharmaceutical Startup Ecosystem, administered by the Japan Agency for Medical Research and Development (AMED). This highly competitive initiative supports early-stage biotech companies and strengthens Japan's pharmaceutical innovation infrastructure. The grant provides non-dilutive capital to fund research and development activities while enabling CORE to establish collaborative partnerships with Japanese universities, hospitals, and the broader biopharma community.
CORE's differentiated technology platform leverages a lineage-based approach to precision oncology therapeutics, designed to identify and target core oncology drivers with precision while potentially expanding the addressable patient populations for its novel therapies. The company operates with headquarters across Boston, Tokyo, and Suzhou, China, positioning it within both developed biotech markets and rapidly growing Asia-Pacific innovation corridors.
The combined $21 million in venture capital and AMED grant support will accelerate development of CORE's lead programs through discovery and early clinical development phases. This dual-track funding strategy—blending private venture investment with government-backed innovation grants—provides CORE with extended runway to advance its precision medicine platform while maintaining operational flexibility in an increasingly competitive oncology therapeutics landscape.
Complementing the venture round, CORE Biomedicine Japan—a wholly owned subsidiary—secured a grant award under Japan's Strengthening Program for Pharmaceutical Startup Ecosystem, administered by the Japan Agency for Medical Research and Development (AMED). This highly competitive initiative supports early-stage biotech companies and strengthens Japan's pharmaceutical innovation infrastructure. The grant provides non-dilutive capital to fund research and development activities while enabling CORE to establish collaborative partnerships with Japanese universities, hospitals, and the broader biopharma community.
CORE's differentiated technology platform leverages a lineage-based approach to precision oncology therapeutics, designed to identify and target core oncology drivers with precision while potentially expanding the addressable patient populations for its novel therapies. The company operates with headquarters across Boston, Tokyo, and Suzhou, China, positioning it within both developed biotech markets and rapidly growing Asia-Pacific innovation corridors.
The combined $21 million in venture capital and AMED grant support will accelerate development of CORE's lead programs through discovery and early clinical development phases. This dual-track funding strategy—blending private venture investment with government-backed innovation grants—provides CORE with extended runway to advance its precision medicine platform while maintaining operational flexibility in an increasingly competitive oncology therapeutics landscape.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.